Cetuximab Concurrent with Radiotherapy in Unresectable, Locally Advanced Squamous Cell Carcinoma of Head and Neck : Real-World Evidence from a Tertiary Care Hospital
© Association of Otolaryngologists of India 2020..
Cetuximab (EGFR-targeted IgG1 monoclonal antibody) has shown to improve the treatment outcomes in head and neck cancer. The evidence on the beneficial outcomes of cetuximab with radiotherapy (RT) in unresectable patients of locally advanced squamous cell carcinoma of head and neck (LA-SCCHN) is limited in real-life practice. The present study evaluated the treatment outcomes of cetuximab concurrent with RT in Indian patients with unresectable LA-SCCHN. We retrospectively reviewed fifty-one patients with unresectable LA-SCCHN between January 2013 and December 2017, who were treated with cetuximab concurrently with RT. Tumor response and disease-free survival (DFS) were estimated. Tumor response using RECIST (1.1) criteria reported complete response in 66.7%, partial response in 31.4% and progressive disease in 1.9% of the patients. The overall response rate was 98%. The 1-year and 2-year DFS was 85% and 69% respectively. The median DFS was significantly better in stage 3 than stage 4. The most common toxicity observed was mucositis and skin reactions (grade 3). Cetuximab concurrent with RT was effective in Indian patients with unresectable, LA-SCCHN and had an acceptable toxicity profile in real-life practice. The real-life beneficial evidence of the combination is consistent with the results documented in the randomized controlled trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India - 74(2022), Suppl 2 vom: 15. Okt., Seite 1857-1863 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rawat, Shyamji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cetuximab |
|---|
| Anmerkungen: |
Date Revised 02.10.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s12070-020-01877-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34965316X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34965316X | ||
| 003 | DE-627 | ||
| 005 | 20231226043134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12070-020-01877-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM34965316X | ||
| 035 | |a (NLM)36452647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rawat, Shyamji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cetuximab Concurrent with Radiotherapy in Unresectable, Locally Advanced Squamous Cell Carcinoma of Head and Neck |b Real-World Evidence from a Tertiary Care Hospital |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Association of Otolaryngologists of India 2020. | ||
| 520 | |a Cetuximab (EGFR-targeted IgG1 monoclonal antibody) has shown to improve the treatment outcomes in head and neck cancer. The evidence on the beneficial outcomes of cetuximab with radiotherapy (RT) in unresectable patients of locally advanced squamous cell carcinoma of head and neck (LA-SCCHN) is limited in real-life practice. The present study evaluated the treatment outcomes of cetuximab concurrent with RT in Indian patients with unresectable LA-SCCHN. We retrospectively reviewed fifty-one patients with unresectable LA-SCCHN between January 2013 and December 2017, who were treated with cetuximab concurrently with RT. Tumor response and disease-free survival (DFS) were estimated. Tumor response using RECIST (1.1) criteria reported complete response in 66.7%, partial response in 31.4% and progressive disease in 1.9% of the patients. The overall response rate was 98%. The 1-year and 2-year DFS was 85% and 69% respectively. The median DFS was significantly better in stage 3 than stage 4. The most common toxicity observed was mucositis and skin reactions (grade 3). Cetuximab concurrent with RT was effective in Indian patients with unresectable, LA-SCCHN and had an acceptable toxicity profile in real-life practice. The real-life beneficial evidence of the combination is consistent with the results documented in the randomized controlled trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cetuximab | |
| 650 | 4 | |a Combined modality therapy | |
| 650 | 4 | |a Head and neck neoplasms/carcinoma | |
| 650 | 4 | |a Monoclonal | |
| 650 | 4 | |a Oral cancer | |
| 650 | 4 | |a Radiotherapy | |
| 700 | 1 | |a Jain, Rajesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Chandraprakash |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India |d 1997 |g 74(2022), Suppl 2 vom: 15. Okt., Seite 1857-1863 |w (DE-627)NLM093661746 |x 2231-3796 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:Suppl 2 |g day:15 |g month:10 |g pages:1857-1863 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12070-020-01877-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e Suppl 2 |b 15 |c 10 |h 1857-1863 | ||